Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

57
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
57
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

46
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
46
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

48
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
48
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

58
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
58
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

44
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
44

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evolving Roles of Primary Cilia in CNS Development and Neural Circuit Function: From Human Disease to Molecular Underpinnings.

The Journal of neuroscience : the official journal of the Society for Neuroscience·2026
Same author

Acute Brain Injury in New-Onset Refractory Status Epilepticus and Etiology-Defined Status Epilepticus.

JAMA neurology·2026
Same author

Deciding whether to donate fetal tissue for research.

BMC medical ethics·2026
Same author

Evaluation of antimicrobial photodynamic therapy with Butyl toluidine blue O for inactivation of Aggregatibacter actinomycetemcomitans biofilm.

Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology·2026
Same author

The impact of delayed evacuation on the quality of human fetal tissue.

PloS one·2026
Same author

Butyl toluidine blue as a photosensitizer for antimicrobial photodynamic therapy on titanium-associated biofilms.

Journal of photochemistry and photobiology. B, Biology·2025
Same journal

Hammersmith Infant Neurological Examination global scores for predicting neurodevelopmental outcomes after 2 years of age: A systematic review and meta-analysis.

Developmental medicine and child neurology·2026
Same journal

Seizure worsening and sodium channel blockers in HCN1-related epilepsies: A case series.

Developmental medicine and child neurology·2026
Same journal

What is the impact of childhood-onset disability research - and what should it be?

Developmental medicine and child neurology·2026
Same journal

Sleep disturbances in children with cerebral palsy, their siblings, and parents: A qualitative descriptive study.

Developmental medicine and child neurology·2026
Same journal

Reframing early socio-emotional risk in infants at high risk of cerebral palsy beyond motor outcomes.

Developmental medicine and child neurology·2026
Same journal

Mitochondrial respiration and characteristics of skeletal muscles in children with cerebral palsy.

Developmental medicine and child neurology·2026
See all related articles

Related Experiment Video

Updated: Oct 28, 2025

Neuronavigation and Laparoscopy Guided Ventriculoperitoneal Shunt Insertion for the Treatment of Hydrocephalus
14:59

Neuronavigation and Laparoscopy Guided Ventriculoperitoneal Shunt Insertion for the Treatment of Hydrocephalus

Published on: October 14, 2022

8.3K

Mortality in pediatric hydrocephalus.

Hannah M Tully1,2,3, Dan Doherty3,4, Mark Wainwright1,2,3

  • 1Division of Pediatric Neurology, Seattle Children's Hospital, Seattle, WA, USA.

Developmental Medicine and Child Neurology
|July 16, 2021
PubMed
Summary
This summary is machine-generated.

Most deaths in childhood-onset hydrocephalus are due to comorbidities, not the condition itself. Goals-of-care decisions and clinician guidance significantly influence end-of-life trajectories for these patients.

More Related Videos

A Pediatric Concussion Model in Mice: Closed Head Injury with Long-Term Disorders (CHILD)
07:01

A Pediatric Concussion Model in Mice: Closed Head Injury with Long-Term Disorders (CHILD)

Published on: February 7, 2025

633
Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock
09:09

Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock

Published on: November 3, 2023

1.2K

Related Experiment Videos

Last Updated: Oct 28, 2025

Neuronavigation and Laparoscopy Guided Ventriculoperitoneal Shunt Insertion for the Treatment of Hydrocephalus
14:59

Neuronavigation and Laparoscopy Guided Ventriculoperitoneal Shunt Insertion for the Treatment of Hydrocephalus

Published on: October 14, 2022

8.3K
A Pediatric Concussion Model in Mice: Closed Head Injury with Long-Term Disorders (CHILD)
07:01

A Pediatric Concussion Model in Mice: Closed Head Injury with Long-Term Disorders (CHILD)

Published on: February 7, 2025

633
Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock
09:09

Description of a Swine Infant Model of Volume-Controlled Hemorrhagic Shock

Published on: November 3, 2023

1.2K

Area of Science:

  • Pediatric Neurology
  • Neurodevelopmental Disorders
  • Medical Ethics

Background:

  • Childhood-onset hydrocephalus is a complex condition requiring long-term management.
  • Understanding mortality factors is crucial for improving patient outcomes and care planning.

Purpose of the Study:

  • To investigate the roles of medical comorbidities and goals-of-care decisions in mortality among individuals with childhood-onset hydrocephalus.
  • To analyze the circumstances surrounding death in this population.

Main Methods:

  • Retrospective cohort study of 1705 individuals with childhood-onset hydrocephalus.
  • Analysis of medical records, death records, and internet sources.
  • Cox regression for risk factor analysis and qualitative analysis of death circumstances.

Main Results:

  • Mortality rates did not differ significantly by demographics, though non-White and Hispanic individuals had higher proportions of deaths.
  • Most deaths were attributed to medical comorbidities, with few directly related to hydrocephalus or shunt complications.
  • Goals-of-care decisions, including forgoing treatment and shifts to comfort care, influenced mortality, particularly when aligned with predicted poor outcomes.

Conclusions:

  • Individuals with childhood-onset hydrocephalus are more likely to die with the condition than from it.
  • Medical comorbidities and end-of-life care decisions, guided by clinicians, are significant factors in mortality.
  • Emphasizes the complexity of medical decision-making in pediatric neurodevelopmental disorders.